Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
The Prospective Randomized Evaluation of the Vascular Effects of Norvase (amlodipine) Trial (PREVENT) was designed specifically to assess if amlodipine can be shown to inhibit angiographic progression of lesions 30% or less diameter stenosis. A carotid ultrasound substudy was also undertaken. The antiatherosclerotic effects were discordant in that minor coronary lesions were not affected, whereas carotid intima-media thickness showed significantly less progression in the amlodipine-treated patients. Moreover, significant cardiac events, particularly admissions to hospital for unstable angina and intervention, were significantly reduced in the amlodipine-treated patients. This brief report provides an overview and assessment of the implications of these findings.
Vancouver Hospital and Health Sciences Centre, Vancouver, Canada. ddavies@vanhosp.bc.ca
G B
GB
Mancini
D017311:Amlodipine / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002340:Carotid Artery Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D002121:Calcium Channel Blockers; D017311:Amlodipine